Transferred from: Medicilon

Recently, the team of Insilico Medicine, an AI-driven clinical-stage biomedical technology company, visited the Chuansha Campus of Shanghai Medicilon Biopharma Co., Ltd. (hereinafter referred to as "Medicilon") to conduct in-depth exchanges on business cooperation in 2024.

"Team Excellence Award".

　　AI+CRO

Empower AI drug R&D to achieve high-quality and efficient delivery

Medicilon's DMPK team continues to empower Insilico Medicine's preclinical program research and development, and has completed a number of key studies such as DMPK package studies and Non-GLP safety evaluation in the PK and IND application stages of oncology projects. In the process of cooperation, Medicilon adheres to systematic, stable and efficient work standards, and achieves the delivery of high-quality research results at the fastest speed, which not only highlights the team's hard-core R&D capabilities and continuous pursuit of excellence in scientific research, but also wins high recognition from partners.

Winning the "Team Excellence Award" this time is not only an affirmation of Medicilon's professional ability and service quality, but also a vivid example of AI+CRO's empowerment of collaborative innovation and integrated development in the biomedical industry.

　　AI+CRO

AI+CRO empowers drug R&D

Medicilon and Insilico Medicine work hand in hand

At the symposium after the award ceremony, the two sides carried out in-depth exchanges around their respective core advantages and needs. The Insilico Medicine team shared the current status and future trends of AI pharma discovery, and proposed the upcoming R&D project plan. Medicilon focused on sharing the team's core capabilities and advantages, and put forward a targeted cooperation plan to support the smooth progress of Insilico Medicine's R&D project, and the two sides reached a broad consensus on deepening cooperation and efficient empowerment, laying a solid foundation for smooth exchanges and cooperation in the future.

At present, the integration of AI and CRO is becoming the core force to promote the transformation of biomedicine. Insilico Medicine has efficiently established more than 30 in-house pipelines based on the Pharma.AI of its AI-powered biopharmaceutical platform, of which 10 molecules have been approved for clinical trials. Since entering into a strategic partnership with Insilico Medicine in 2021, Medicilon has provided consistent and efficient and consistent support and empowerment for the preclinical development of its projects.

In addition, Medicilon continues to expand its business according to the needs of the industry, and has built an AI drug discovery service platform in addition to traditional pharmaceutical chemistry contract research and development services, as well as a one-stop preclinical service platform involving a variety of new therapies such as PROTACs, ADCs, nucleic acid drugs, bispecific antibodies, peptides, vaccines, and cell and gene therapy, enabling about 520 IND approvals for clinical trials. The cooperation between the two parties interprets the practical path of AI+CRO empowering biomedical R&D.

The affirmation of customers is the greatest praise for Medicilon! Medicilon will take this as a spur and rely on the one-stop biomedical preclinical comprehensive R&D service platform to continue to empower AI drug R&D, and actively explore new applications and models of AI in drug R&D, so as to provide more efficient and high-quality R&D solutions for new drug R&D, help global pharmaceutical companies seize opportunities on the competitive track, and jointly promote the prosperity and development of the biopharmaceutical industry.

About Insilico Medicine

Insilico Medicine is a clinical-stage biotech company powered by generative AI that connects biology, chemistry, clinical medicine, and scientific research through next-generation AI systems, leveraging modern machine learning technologies such as deep generative models, reinforcement learning, and transformation models to build a powerful and efficient AI drug discovery platform to identify novel targets and generate drug candidates with specific molecular structures. Insilico Medicine is advancing and accelerating the development of innovative medicines with a focus on unmet medical needs such as cancer, fibrosis, immunity, central nervous system diseases, and aging-related diseases.

Medicilon (stock code: 688202.HK) Founded in 2004 and headquartered in Shanghai, SH is committed to providing a full range of preclinical new drug research services for global pharmaceutical companies, research institutions and researchers. Medicilon's one-stop comprehensive service helps customers accelerate the process of new drug development with strong project management and more efficient and cost-effective R&D services, covering the whole process of pharmaceutical preclinical new drug research, including drug discovery, pharmaceutical research and preclinical research. By the end of 2024, Medicilon has provided drug R&D services to more than 2,000 customers around the world, and has participated in the research and development of about 520 IND clinical trials of new drugs and generic drugs, growing together with high-quality customers at home and abroad. Medicilon will continue to be based on a global vision, focus on China's innovation, and contribute to human health!

(Redirected from: Medicilon).